Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials |
| Type de publication | Journal Article |
| Year of Publication | 2018 |
| Auteurs | Aparicio T, Ducreux M, Faroux R, Barbier E, Manfredi S, Lecomte T, Etienne P-L, Bedenne L, Bennouna J, Phelip J-M, Francois E, Michel P, Legoux J-L, Gasmi M, Breysacher G, Rougier P, de Gramont A, Lepage C, Bouche O, Seitz J-F, Investigators FFCD |
| Journal | EUROPEAN JOURNAL OF CANCER |
| Volume | 98 |
| Pagination | 1-9 |
| Date Published | JUL |
| Type of Article | Article; Proceedings Paper |
| ISSN | 0959-8049 |
| Mots-clés | Bevacizumab, Colorectal cancer, Overweight, Pooled analysis, Prognostic factor |
| Résumé | {Background: Previous studies showed that high and low body mass index (BMI) was associated with worse prognosis in early-stage colorectal cancer (CRC), and low BMI was associated with worse prognosis in metastatic CRC (mCRC). We aimed to assess efficacy outcomes according to BMI. Patients and methods: A pooled analysis of individual data from 2085 patients enrolled in eight FFCD first-line mCRC trials from 1991 to 2013 was performed. Comparisons were made according to the BMI cut-off: Obese (BMI >= 30), overweight patients (BMI >= 25), normal BMI patients (BMI: 18.5-24) and thin patients (BMI <18.5). Interaction tests were performed between BMI effect and sex, age and the addition of antiangiogenics to chemotherapy. Results: The rate of BMI >= 25 patients was 41.5%, ranging from 37.6% (1991-1999 period) to 41.5% (2000-2006 period) and 44.8% (2007-2013 period). Comparison of overweight patients versus normal BMI range patients revealed a significant improvement of median overall survival (OS) (18.5 versus 16.3 months |
| DOI | 10.1016/j.ejca.2018.03.031 |